1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC) - Vansteenkiste, J.F.; Demedts, I.; Pons-Tostivint, E.; Biesma, B.; Borm, F.; Colinet, B.; Cuppens, K.; Derijcke, S.; Greillier, L.; Jürgens, J.; Moro-Sibilot, D.; Pérol, M.; et al. (Annals of Oncology, 2022)